LA ROCHE POSAY Lipikar Baume AP+M

It is the perfect body balm to get rid of severe dry, itchy and eczema-prone skin on babies, children and adults. Lipikar Balm AP+M is clinically proven to reduce itching by half, provide immediate soothing and space out the frequency of flare-ups of eczema and severe dryness. The new AP+M triple-action formula has a reinforced anti-scratching, anti-relapse efficacy and rebalances the skin’s microbiome. It replenishes skin’s essential lipids to strengthen its moisture barrier and provides long-lasting 48-hour hydration. It can be used on the face, hands and body and is suitable for adults, children and babies as young as 2 weeks, for use all year round.

The soothing balm quickly absorbs into the skin and is non-greasy with a non-sticky finish, leaving the skin soft and comforted from sensitivities.

La Roche-Posay research has shown that to provide lasting relief from eczema-prone skin, you need to rebalance its microbiome, the invisible living ecosystem of bacteria on your skin. This knowledge inspired the formula of Lipikar Balm AP+M, which provides a triple-action efficacy for atopic skin: 1) on the microbial barrier to rebalance the skin microbiome; 2) on the skin’s moisture barrier to reduce transepidermal water loss; and 3) on the immune barrier to decrease inflammation, helping reduce pain sensation, itching and relapse. It soothes skin immediately and reduces scratching. With its anti-relapse efficacy, it spaces out flare-ups of severe dryness, nourishes skin, and helps restore the skin’s moisture barrier.

Spaces out the frequency of flare-ups of severe dryness
Immediate soothing, reduces pain sensations
2x less itching
2x less relapse*
48-hour hydration
Rebalances your skin’s microbiome
Reduces areas of dry and rough skin
Clinical results of routine use with Lipikar Syndet AP+**:

41% reduction in itching sensations
42% decrease in sleep loss
69% improvement in quality of life
*3,787 patients, with continuous use, 1 application/day, severe dryness peaks are spaced out.

**Clinical study on 51 subjects (children and adults) for 2 weeks.